RxDoctor Payments Data

Jose Delagandara

West Palm Beach, FLNPI 1265432041

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $766 of the $1,262 with a category attached, or 60.7%. 5 manufacturers reported payments, led by Grifols Biologicals LLC at 44.6% of the total. Reporting peaked in 2019 at $1,022 and has fallen 87.8% since, to $125 in 2023.

$1,262in general payments, 2019–2025

Across 10 payments — averaging $126.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Grifols Biologicals LLC$563
  • Eisai Inc.$367
  • Otsuka America Pharmaceutical, Inc.$125
  • Livanova USA, Inc.$116
  • Genentech USA, Inc.$92
$4,501,087in research payments, 2019–2025

Across 320 payments — averaging $14,066 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eisai Inc.$2.4M
  • Biogen$859K
  • Eli Lilly$539K
  • Grifols Biologicals LLC$241K
  • E.r. Squibb & Sons, L.L.C.$182K
  • Avanir Pharmaceuticals, Inc.$109K
  • plus $194K from 7 others

What the payments were for

  • Travel & lodging$76661%
  • Food & beverage$49639%

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lamotrigine12$98
Clonazepam11$16

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →